Photo of Dennis Bourdette, M.D., F.A.A.N.

Dennis Bourdette M.D., F.A.A.N.

    • Professor of Neurology School of Medicine
    • Dr.Roy and Eulalia Swank family research professor Neurology School of Medicine
    • Director OHSU Multiple Sclerosis Center School of Medicine
    • Neuroscience Graduate Program School of Medicine
    • Jungers Center for Neurosciences Research

Dr. Bourdette is chair of the Department of Neurology, Roy and Eulalia Swank family research professor, executive director of the OHSU Multiple Sclerosis Center and co-director of the VA MS Center of Excellence-West. He directs a team dedicated to curing and treating diseases such as multiple sclerosis, Alzheimer’s, Parkinson’s, stroke, and ALS.

He is nationally recognized for his important discoveries in the field of multiple sclerosis and oversees an annual research budget of over $2 million. His team has attracted grants from the National Institutes of Health, Department of Veterans Affairs, National MS Society, Nancy Davis Foundation for Multiple Sclerosis, to name a few. He and his colleagues have received international attention for their development of a TCR peptide vaccine called Neurovax for the treatment of multiple sclerosis and a new therapy called VG1000 being developed with a local biotechnology company, Virogenomics. Dr. Bourdette received his medical degree at the University of California at Davis, joined OHSU in 1984 as a resident in the Department of Neurology.

Read more


  • M.D., University of California-Davis Medical School 1978
  • Residency:

    • Medicine – Santa Clara Valley Medical Center, San Jose
    • Neurology – Oregon Health & Science University
  • Fellowship:

    • Neuroimmunology – Veterans Affairs Medical Center, Portland

Memberships and associations

  • American Board of Neurology and Psychiatry, 1985


  • "Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months : A randomized clinical trial." Multiple Sclerosis Journal  In: , 01.07.2018.
  • "A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis : Long-term (12-month) follow-up at one site." Multiple Sclerosis Journal  In: , 01.05.2018.
  • "Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis." British Journal of Ophthalmology  In: , Vol. 102, No. 4, 01.04.2018, p. 520-524.
  • "In reply." JAMA Internal Medicine In: , Vol. 178, No. 4, 01.04.2018, p. 583-584.
  • "Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis." Journal of Neuroimmunology  In: , Vol. 315, 15.02.2018, p. 24-27.
  • "Elephant in the room." Annals of the Rheumatic Diseases In: , 23.01.2018.
  • "Meals, Mindfulness, & Moving Forward : A feasibility study to a multi-modal lifestyle approach in early psychosis." Early Intervention in Psychiatry  In: , 01.01.2018.
  • "A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis : Short- and medium-term benefits." Multiple Sclerosis Journal  In: , 01.12.2017.
  • "Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy." ACS Chemical Neuroscience In: , Vol. 8, No. 11, 15.11.2017, p. 2468-2476.
  • "Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects." Molecular Neurobiology  In: , 15.11.2017, p. 1-13.
  • "Trends and characteristics of US Medicare spending on repository corticotropin." JAMA Internal Medicine In: , Vol. 177, No. 11, 01.11.2017, p. 1680-1682.
  • "Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis : Results from a clinical trial cohort." Multiple Sclerosis Journal In: , 01.11.2017.
  • "MIF and D-DT are potential disease severity modifiers in male MS subjects." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 114, No. 40, 03.10.2017, p. E8421-E8429.
  • "Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?" Neurology  In: , Vol. 89, No. 11, 01.09.2017, p. 1098-1100.
  • "Sleep and its associations with perceived and objective cognitive impairment in individuals with multiple sclerosis." Journal of Sleep Research In: , Vol. 26, No. 4, 01.08.2017, p. 428-435.
  • "Author response : Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness." Neurology In: , Vol. 89, No. 5, 01.08.2017, p. 520-521.
  • "Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials." Current Neurology and Neuroscience Reports  In: , Vol. 18, No. 8, 49, 01.08.2017.
  • "MS and bone marrow transplant : Not for most patients." Neurology  In: , Vol. 88, No. 22, 30.05.2017, p. e219.
  • "About multiple sclerosis and hematopoietic stem cells in the treatment of multiple sclerosis." Neurology  In: , Vol. 88, No. 22, 30.05.2017, p. e220.
  • "Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration." Bioorganic and Medicinal Chemistry In: , Vol. 25, No. 10, 15.05.2017, p. 2743-2753.
  • "Sex-dependent treatment of chronic EAE with partial MHC class II constructs." Journal of Neuroinflammation In: , Vol. 14, No. 1, 100, 06.05.2017.
  • "Early Fever As a Predictor of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury." Journal of Head Trauma Rehabilitation  In: , 05.01.2017.
  • "Lipoic acid in secondary progressive MS." Neurology: Neuroimmunology and NeuroInflammation  In: , Vol. 4, No. 5, 374, 2017.
  • "Lipoic acid pharmacokinetics at baseline and 1 year in secondary progressive MS." Neurology: Neuroimmunology and NeuroInflammation  In: , Vol. 4, No. 5, 380, 2017.
  • "Rituximab for treating multiple sclerosis." Neurology  In: , Vol. 87, No. 20, 15.11.2016, p. 2070-2071.
  • "Neurologists and the economics of MS treatment : Lighting candles, not cursing the darkness." Neurology  In: , Vol. 87, No. 15, 11.10.2016, p. 1532-1533.
  • "The contemporary spectrum of multiple sclerosis misdiagnosis." Neurology In: , Vol. 87, No. 13, 27.09.2016, p. 1393-1399.
  • "Low-fat, plant-based diet in multiple sclerosis : A randomized controlled trial." Multiple Sclerosis and Related Disorders  In: , Vol. 9, 01.09.2016, p. 80-90.
  • "US health insurance is an obstacle to disease-modifying treatments in MS." Neurology  In: , Vol. 87, No. 4, 26.07.2016, p. 346-347.
  • "Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells." Biochemical and Biophysical Research Communications  In: , Vol. 475, No. 1, 17.06.2016, p. 19-24.

Additional information

Edit profile